Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1997 Dec;50(12):975–980. doi: 10.1136/jcp.50.12.975

Neurological paraneoplastic syndromes.

U Nath 1, R Grant 1
PMCID: PMC500375  PMID: 9516876

Abstract

Paraneoplastic neurological syndromes are uncommon, however, their diagnosis is of major practical importance. The identification of antibodies in the serum or cerebrospinal fluid in central nervous system paraneoplastic syndromes confirms the clinical diagnosis of a paraneoplastic syndrome and allows early identification of an underlying tumour at a stage when it is localised and more amenable to treatment. The failure to identify antibodies in patients with characteristic presentations of underlying neurological paraneoplastic syndromes does not exclude an underlying cancer. Necrotising myelopathy, dermatomyositis, and chronic inflammatory demyelinating polyneuropathy all occur more frequently than expected in patients with cancer but autoantibodies have not yet been identified. Although significant advances have been made in diagnosis, further research is needed in the detection of autoantibodies and the elucidation of their role in the aetiology of neurological disease.

Full text

PDF
978

Images in this article

975Image
on p.975
977Image
on p.977
978Image
on p.978

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson N. E., Cunningham J. M., Posner J. B. Autoimmune pathogenesis of paraneoplastic neurological syndromes. Crit Rev Neurobiol. 1987;3(3):245–299. [PubMed] [Google Scholar]
  2. Blumenfeld A. M., Recht L. D., Chad D. A., DeGirolami U., Griffin T., Jaeckle K. A. Coexistence of Lambert-Eaton myasthenic syndrome and subacute cerebellar degeneration: differential effects of treatment. Neurology. 1991 Oct;41(10):1682–1685. doi: 10.1212/wnl.41.10.1682. [DOI] [PubMed] [Google Scholar]
  3. Dalmau J., Furneaux H. M., Gralla R. J., Kris M. G., Posner J. B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol. 1990 May;27(5):544–552. doi: 10.1002/ana.410270515. [DOI] [PubMed] [Google Scholar]
  4. Dalmau J., Furneaux H. M., Rosenblum M. K., Graus F., Posner J. B. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology. 1991 Nov;41(11):1757–1764. doi: 10.1212/wnl.41.11.1757. [DOI] [PubMed] [Google Scholar]
  5. Dalmau J., Posner J. B. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology. 1994 Dec;44(12):2241–2246. doi: 10.1212/wnl.44.12.2241. [DOI] [PubMed] [Google Scholar]
  6. Fukuhara N., Takamori M., Gutmann L., Chou S. M. Eaton-Lambert syndrome. Ultrastructural study of the motor end-plates. Arch Neurol. 1972 Jul;27(1):67–78. doi: 10.1001/archneur.1972.00490130069009. [DOI] [PubMed] [Google Scholar]
  7. Furneaux H. F., Reich L., Posner J. B. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990 Jul;40(7):1085–1091. doi: 10.1212/wnl.40.7.1085. [DOI] [PubMed] [Google Scholar]
  8. Graus F., Elkon K. B., Cordon-Cardo C., Posner J. B. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med. 1986 Jan;80(1):45–52. doi: 10.1016/0002-9343(86)90047-1. [DOI] [PubMed] [Google Scholar]
  9. Hermans P. E. The clinical manifestations of infective endocarditis. Mayo Clin Proc. 1982 Jan;57(1):15–21. [PubMed] [Google Scholar]
  10. Lambert E. H. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci. 1966 Jan 26;135(1):367–384. doi: 10.1111/j.1749-6632.1966.tb45484.x. [DOI] [PubMed] [Google Scholar]
  11. Lang B., Newsom-Davis J., Wray D., Vincent A., Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981 Aug 1;2(8240):224–226. doi: 10.1016/s0140-6736(81)90474-8. [DOI] [PubMed] [Google Scholar]
  12. Lennon V. A. Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature. Neurology. 1994 Dec;44(12):2236–2240. doi: 10.1212/wnl.44.12.2236. [DOI] [PubMed] [Google Scholar]
  13. Luque F. A., Furneaux H. M., Ferziger R., Rosenblum M. K., Wray S. H., Schold S. C., Jr, Glantz M. J., Jaeckle K. A., Biran H., Lesser M. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991 Mar;29(3):241–251. doi: 10.1002/ana.410290303. [DOI] [PubMed] [Google Scholar]
  14. Moll J. W., Antoine J. C., Brashear H. R., Delattre J., Drlicek M., Dropcho E. J., Giometto B., Graus F., Greenlee J., Honnorat J. Guidelines on the detection of paraneoplastic anti-neuronal-specific antibodies: report from the Workshop to the Fourth Meeting of the International Society of Neuro-Immunology on paraneoplastic neurological disease, held October 22-23, 1994, in Rotterdam, The Netherlands. Neurology. 1995 Oct;45(10):1937–1941. doi: 10.1212/wnl.45.10.1937. [DOI] [PubMed] [Google Scholar]
  15. Moll J. W., Markusse H. M., Pijnenburg J. J., Vecht C. J., Henzen-Logmans S. C. Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome. Neurology. 1993 Dec;43(12):2574–2581. doi: 10.1212/wnl.43.12.2574. [DOI] [PubMed] [Google Scholar]
  16. Nausieda P. A., Tanner C. M., Weiner W. J. Opsoclonic cerebellopathy: A paraneoplastic syndrome responsive to thiamine. Arch Neurol. 1981 Dec;38(12):780–781. doi: 10.1001/archneur.1981.00510120080015. [DOI] [PubMed] [Google Scholar]
  17. Ridley A., Kennard C., Scholtz C. L., Büttner-Ennever J. A., Summers B., Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain. 1987 Dec;110(Pt 6):1699–1709. doi: 10.1093/brain/110.6.1699. [DOI] [PubMed] [Google Scholar]
  18. Rosenfeld M. R., Wong E., Dalmau J., Manley G., Posner J. B., Sher E., Furneaux H. M. Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol. 1993 Jan;33(1):113–120. doi: 10.1002/ana.410330126. [DOI] [PubMed] [Google Scholar]
  19. Ross A. T., Zeman W. Opsoclonus, occult carcinoma, and chemical pathology in dentate nuclei. Arch Neurol. 1967 Nov;17(5):546–551. doi: 10.1001/archneur.1967.00470290100013. [DOI] [PubMed] [Google Scholar]
  20. Sillevis Smitt P. A., Manley G. T., Posner J. B. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology. 1995 Oct;45(10):1873–1878. doi: 10.1212/wnl.45.10.1873. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES